Dago Bio Completes Over $20 Million A+ Round Funding to Accelerate Novel Molecular Glue Drug Development

Dago Bio Completes Over $20 Million A+ Round Funding to Accelerate Novel Molecular Glue Drug DevelopmentLate 2024, Dago Bio (hereinafter referred to as Dago), a biotechnology company focused on developing molecular glue drugs targeting undruggable targets, announced the successful completion of a Series A+ financing round exceeding $20 million. This round was co-led by Zhejiang Province's "4+1" Biomedicine and High-end Medical Device Industry Fund, Takeda Ventures, Fengchuan Capital, Longmen Capital, HaoYue China Healthcare Fund, and AIM-HI Accelerator Fund...

Tech >>